NCT00006245CompletedPhase 2
Phase II Trial of Flavopiridol and Paclitaxel in Patients With Paclitaxel-Refractory Esophageal Cancer
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Locations
- 1
Study Overview
Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining flavopiridol and paclitaxel in treating patients who have locally advanced or metastatic esophageal cancer that has not responded to previous paclitaxel therapy.
Detailed Description
OBJECTIVES:
- Determine the response rate in patients with paclitaxel-refractory locally advanced or metastatic esophageal cancer treated with sequential paclitaxel and flavopiridol.
- Determine the toxicity of this regimen in these patients.
- Assess the quality of life of patients treated with this regimen.
- Obtain pharmacokinetic information about this regimen.
OUTLINE: This is a multicenter study.
Patients receive paclitaxel IV over 3 hours on day 1 and flavopiridol IV continuously over 24 hours on day 2 weekly for 3 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, after courses 1 and 2, and then every 2 courses thereafter.
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus or carcinoma of the gastroesophageal (GE) junction
- •If tumor extends below the GE junction into the proximal stomach, 50% of the tumor must involve the esophagus or GE junction
- •No gastric cancers with only a minor involvement of the GE junction or distal esophagus
- •Metastatic or locally advanced disease that is considered surgically unresectable
- •Must have failed a prior chemotherapy regimen that included paclitaxel for metastatic disease OR
- •Failed prior combination taxane-based chemotherapy and radiotherapy for locally advanced disease
- •Must have documented evidence of the following:
- •Disease progression while on taxane-based neoadjuvant or adjuvant therapy OR
- •Recurrent disease within 6 months of therapy
- •Measurable disease
- •Accurately measured in at least 1 dimension
- •At least 20 mm by conventional techniques OR
- •At least 10 mm by spiral CT scan
- •The following are considered nonmeasurable:
- •Bone lesions
- •Leptomeningeal disease
- •Pleural/pericardial effusions
- •Inflammatory breast disease
- •Lymphangitis cutis/pulmonis
- •Abdominal masses that are not confirmed and followed by imaging techniques
- •Cystic lesions
- •No brain metastases
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status:
- •Karnofsky 70-100%
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •Absolute granulocyte count at least 1,500/mm^3
- •Platelet count at least 150,000/mm^3
- •Bilirubin no greater than 1.5 mg/dL
- •Creatinine no greater than 1.5 mg/dL
- •Cardiovascular:
- •No active angina or myocardial infarction within the past 6 months
- •No significant ventricular arrhythmia requiring antiarrhythmic medication
- •Atrial fibrillation that is well controlled on standard management allowed
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for 2 months after study
- •No preexisting peripheral neuropathy of grade 2 or greater
- •No serious concurrent infection
- •No uncontrolled, nonmalignant medical illness that would preclude study
- •HIV negative
- •No other active malignancy within the past 5 years except:
- •Nonmelanoma skin cancer or
- •Carcinoma in situ of the cervix
- •History of T1a or T1b prostate cancer (detected incidentally during transurethral resection of the prostate and comprising less than 5% of resected tissue) allowed if PSA normal since surgery
- •No medical or psychiatric condition that would preclude study compliance
- +17 more not shown
Exclusion Criteria
- Not provided
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial CancerEndometrial CancerNCT00003127SWOG Cancer Research Network57
Completed
Phase 2
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyProstate CancerNCT00049257Jonsson Comprehensive Cancer Center58
Completed
Phase 2
Flavopiridol in Treating Patients With Metastatic Malignant MelanomaMelanoma (Skin)NCT00005971NCIC Clinical Trials Group17
Completed
Phase 2
Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue SarcomaSarcomaNCT00005974NCIC Clinical Trials Group18
Completed
Phase 2
S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung CancerLung CancerNCT00004137SWOG Cancer Research Network88